Four men from Lynn, Massachusetts, received a combined sentence exceeding 57 years in federal prison for their roles in a darknet conspiracy that sold approximately 9,000 counterfeit pills laced with fentanyl and other dangerous substances, resulting in more than a dozen fatal overdoses [1]. The final defendant, Daniel John Blaney, was sentenced to more than 18 years, closing out the prosecution in the Eastern District of Virginia [1]. The other defendants, Kenneth Emmanuel Lora, David Robert Kable Jr., and Javier Alexander Bermudez, were sentenced in earlier proceedings in the same case [1].
The conspiracy ran from May 2022 through June 2025 [1]. The group manufactured and distributed counterfeit oxycodone, Adderall, and Xanax tablets that were adulterated with fentanyl, synthetic Nitazenes, methamphetamine, and Bromazolam [1]. Synthetic Nitazenes are estimated to be up to 40 times more potent than fentanyl [1]. Sales were conducted through darknet marketplaces, which provide buyers and sellers a degree of anonymity through encrypted browsing tools. Federal statutes governing drug trafficking, including 21 U.S.C. § 841 and conspiracy provisions under § 846, formed the basis for the charges. The case was investigated by Homeland Security Investigations and the High Intensity Drug Trafficking Area task force [1].
The Eastern District of Virginia, a favored venue for complex federal drug and cyber-adjacent prosecutions, handled the case despite the defendants' Massachusetts domicile, reflecting the jurisdictional reach available to federal prosecutors when darknet platforms and interstate distribution are involved [1]. The Department of Justice characterized the outcome as illustrative of its commitment to dismantling darknet fentanyl supply chains responsible for mass fatalities [1].
With all four defendants now sentenced, the immediate prosecution is closed. The broader investigative record, including evidence of pill manufacturing infrastructure and darknet marketplace accounts, may support related prosecutions or be shared with interagency partners targeting surviving nodes of the same distribution network. The Nitazene component is likely to draw continued regulatory and law enforcement attention, as that class of synthetic opioids remains incompletely scheduled under federal controlled substances law and represents an evolving enforcement challenge for prosecutors and the Drug Enforcement Administration alike.